NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia

Key Takeaways Novartis reported positive phase III ALIGN results for Vanrafia in IgA nephropathy.Vanrafia slowed eGFR decline vs placebo, with benefits seen through week 136.Novartis plans to seek traditional approval in 2026 after U.S. and China accelerated nods.Novartis (NVS) announced positive results from the late-stage III ALIGN study on kidney disease drug Vanrafia (atrasentan).The ALIGN study is a global, randomized, multicenter, double-blind, placebo-controlled trial evaluating the efficacy and safe ...